News
I have to confess that between my husband and me, we are not very “street smart” when it comes to raising teenagers. I’m embarrassed...
Hi, what are you looking for?
iFintechWorld
iFintechWorld
News
This article was written by Follow Investing in high-growth opportunities across industries, employing a value investing approach that prioritizes robust business models and strategic...
News
This article was written by Follow I’m a full time value investor and writer who enjoys using classical value ratios to pick my portfolio....
News
This article was written by Follow Buffett-style rational value picks | Top 95th percentile of financial bloggers according to TipRanks.Six years of long-horizon investment...
News
X Financial (NYSE:XYF) Q3 2023 Results Conference Call November 22, 2023 9:00 PM ET Company Participants Victoria Yu – Investor Relations Kan Li –...
News
Investment Thesis In my opinion, Bristol-Myers Squibb (NYSE:BMY) stands at a critical juncture. My forthcoming analysis contends that the company’s valuation and future market...
News
In my last post, I initiated coverage of Algoma Steel (NASDAQ:ASTL), explaining my reasoning that through Algoma Steel’s current cost model with its Basic...
News
Stock Overview In my second research note lately covering a utilities sector stock, Duke Energy (NYSE:DUK) is next up in my crosshairs after its...
News
There are as many prudent dividend strategies as there are dividend investors. However, in this report, we review three specific income-focused portfolio strategies, including:...
News
Here at the Lab, we have a good grip on EU semis. Following STMicroelectronics’ 20% stock price decline and a Q3 supportive comment, today...
News
This article was written by Seeking Alpha’s transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands...
News
Thesis The trade of the year in 2023 has been to be long the so called ‘Magnificent Seven’: Alphabet (GOOGL), Apple (AAPL), Amazon (AMZN),...
News
Intro Neurodegenerative disease-focused BioVie (NASDAQ:BIVI) recently presented a set of blinded data which, if taken at face value, suggest that its lead asset NE3107...
